What if... We could harness the power of Flagship’s scientific platforms and create novel treatment options that benefit more patients, sooner?
Pioneering Medicines, an initiative of Flagship Pioneering, is building a world-class biopharmaceutical R&D capability focused on conceiving and developing life-changing treatments for patients by harnessing the power of Flagship's scientific platforms and applying those innovative approaches to serious diseases with unmet medical need. Unique to Pioneering Medicines’ approach is the opportunity to combine platforms to create truly novel and potentially transformative treatments.
About Flagship Pioneering:
Flagship Pioneering is a biotechnology company that invents and builds platform companies that change the world. We bring together the greatest scientific minds with entrepreneurial company builders and assemble the capital to allow them to take courageous leaps. Those big leaps in human health and sustainability exponentially accelerate scientific progress in areas ranging from cancer detection and treatment to nature-positive agriculture.
What sets Flagship apart is our ability to advance biotechnology by uniting life science innovation, company creation, and capital investment under one roof in a way that is largely without precedent. Our scientific founders, entrepreneurial leaders, and professional capital managers are each aligned around an institutionalized process that enables us to innovate and transform for the benefit of people and planet.
Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.
Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies.
Job Summary:
We are seeking a RA/SRA who will be responsible for developing and performing in vitro studies for mechanism of action and efficacy of novel biological and/or small molecule therapeutic agents, including antibody or peptide based approaches to support drug discovery efforts across multiple programs from target validation to human translation.
The ideal candidate will be skillful in cell-based assays with cell lines as well as primary cells from rodent, NHP and human origin. Previous in vitro experience with primary cells (eg: adipocytes, myotubes, hepatocytes etc.) is highly desired. The position will require ability to work in a fast-paced environment on multiple tasks, quickly learn new techniques, organize tasks efficiently and keep records accurately. Ability to interact well with scientific colleagues and work effectively in a team-oriented environment will be necessary.
Responsibilities:
- Perform laboratory-based assays in BSL2/ BSL2+ environment for validation of potential drug development targets and to characterize diverse therapeutics.
- Independently conduct experiments and analyze data.
- Operate and maintain the relevant equipment.
- Maintain electronic notebook.
Requirements:
- Bachelor or Master of Science degree with a minimum of 2 years’ experience in a laboratory of academia or industry.
- Prior working experience with in vitro cell based pharmacology assays using human or rodent primary cells.
- Prior working experience with rodent tissue or plasma samples is a plus.
- Proficient in assay development for testing compounds across different modalities.
- Hands-on experience with cell-based and molecular biology assays, such as flow cytometry, immunoblot, ELISA/MSD and qPCR etc.
Flagship Pioneering Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Flagship Pioneering and has not been reviewed or approved by Flagship Pioneering.
-
Fair & Transparent Compensation — Feedback suggests salary bands are visible for many Boston/Cambridge roles and pay is considered competitive for key scientific and leadership positions. Transparency in postings supports expectations that offers align with local biotech norms.
-
Healthcare Strength — Feedback suggests medical, dental, vision, disability, life insurance, HSA options, and mental-health coverage are comprehensive and well-regarded. Multiple items are employer-verified, reinforcing confidence in core health benefits.
-
Parental & Family Support — Feedback suggests maternity/paternity leave and family leave are offered at meaningful levels. These programs sit alongside paid holidays, sick days, and PTO to support family needs.
Flagship Pioneering Insights
Similar Jobs
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions. The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
